MaxCyte, Inc.
MXCT
Rank in Stocks
#18417
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes... MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Share Price
$1.30
Last synced: 2026-11-09
Market Cap
$134.17M
Change (1 day)
3.17%
Change (1 year)
-17.72%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade MaxCyte, Inc. (MXCT)
Category
Healthcare
P/S ratio for MaxCyte, Inc. (MXCT)
P/S ratio as of November 2026 TTM: 5.28
According to MaxCyte, Inc.'s latest financial reports and stock price, its current price-to-sales ratio (TTM) is 5.28. At the end of 2025 the company had a P/S ratio of 4.99.
P/S ratio history for MaxCyte, Inc. from 2012 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| 2026 (TTM) | 5.28 | 5.91% |
| 2025 | 4.99 | -55.77% |
| 2024 | 11.29 | -3.94% |
| 2023 | 11.76 | -6.30% |
| 2022 | 12.55 | -53.95% |
| 2021 | 27.24 | -39.63% |
| 2020 | 45.13 | 1.76% |
| 2019 | 44.34 | -15.06% |
| 2018 | 52.21 | -11.71% |
| 2017 | 59.13 | 27.33% |
| 2016 | 46.44 | -41.62% |
| 2015 | 79.55 | 2,807.24% |
| 2014 | 2.74 | -97.48% |
| 2013 | 108.60 | -25.65% |
| 2012 | 146.06 | 0.00% |
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 11.22 | 112.32% |
US
|
|
| 39.73 | 651.78% |
US
|
|
| 4.30 | -18.55% |
AU
|
|
| 6.29 | 19.10% |
BE
|
|
| 12.68 | 139.92% |
NL
|
Questions about MaxCyte, Inc.'s P/S ratio
What is MaxCyte, Inc.'s P/S ratio?
MaxCyte, Inc.'s P/S ratio is 5.28, as of Nov 2026.
What was MaxCyte, Inc.'s P/S ratio in 2025?
In 2025, MaxCyte, Inc.'s P/S ratio was 4.99, compared with 11.29 in 2024.
How has MaxCyte, Inc.'s P/S ratio changed since 2020?
From 2020 to 2025, MaxCyte, Inc.'s P/S ratio was highest in 2020 (45.13) and lowest in 2025 (4.99).
How does MaxCyte, Inc.'s P/S ratio compare with similar companies?
MaxCyte, Inc.'s P/S ratio (5.28) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Moderna, Inc., with 39.73.